A vaccine's ability to generate long-lasting, high-affinity antibodies hinges on a delicate balance. Upon exposure to a ...
Germinal centers are high-speed evolution machines. Tiny clusters in the lymph nodes, germinal centers refine antibodies ...
An Australian startup has unveiled the world’s first commercial biologic. Melbourne-based Cortical Labs launched the CL1 at ...
Dysfunctional CD11c − CD21 − extrafollicular memory B cells are enriched in the periphery and tumors of patients with cancer. Science Translational Medicine , 2025; 17 (786) DOI: 10.1126 ...
Hosted on MSN2mon
CAR Natural Killer Cell Therapy Shows Promise in B-Cell LymphomasAn investigational induced pluripotent stem cell-derived CAR natural ... among patients with B-cell lymphomas, according to results from a phase I first-in-human trial. For the 86 patients ...
We focused on developing fully human scFv CARs for CD19 as a target because CARs with murine scFvs are effective in inducing remissions in patients with relapsed and refractory B-cell malignancies.
Being fruitful, they multiply into a ball of many cells, a shimmering sphere of human potential. Scientists have long dreamed of plucking those naive cells from a young human embryo and coaxing ...
has been granted a non-exclusive license to use Nona's H2L2 Harbour Mice ® platform to develop fully human antibodies. This will enable UAB researchers to pursue breakthroughs in B cell ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback